Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Purity: ≥98%
Selisistat (formerly SEN-0014196; EX-527) is a novel, highly potent and selective inhibitor of SIRT1 (Sirtuin1, a NAD-dependent and class III histone deacetylase enzyme) with important biological activity. It inhibits SIRT1 with an IC50 of 38 nM in a cell-free assay, and exhibits >200-fold higher selectivity for SIRT1 over SIRT2, SIRT3 and other deacetylases as well as NAD-processing enzymes.
ln Vitro |
Selisistat (1-10 μM) decreases the deacetylation activity of both human SirT1 and Drosophila Sir2 in transfected cells[1].
|
||
---|---|---|---|
ln Vivo |
In the R6/2 mouse model of Huntington's disease (HD), selenisistat (5 and 20 mg/kg, PO, daily; transgenic R6/2 mice commencing at 4.5 weeks of age until death) is protective[1].
|
||
Animal Protocol |
|
||
References |
[1]. Smith MR, et al. A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease. Hum Mol Genet. 2014;23(11):2995-3007.
[2]. Napper AD, et al. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1 [published correction appears in J Med Chem. 2007 Mar 8;50(5):1086]. J Med Chem. 2005;48(25):8045-8054 |
Molecular Formula |
C13H13CLN2O
|
---|---|
Molecular Weight |
248.71
|
CAS # |
49843-98-3
|
Related CAS # |
(S)-Selisistat;848193-68-0;(R)-Selisistat;848193-69-1
|
SMILES |
O=C(C1C(NC2=C3C=C(Cl)C=C2)=C3CCC1)N
|
Chemical Name |
6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide
|
Synonyms |
Selisistat; EX 527; SEN 0014196; EX527; SEN-0014196; SEN0014196; EX-527
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 4.0207 mL | 20.1037 mL | 40.2075 mL | |
5 mM | 0.8041 mL | 4.0207 mL | 8.0415 mL | |
10 mM | 0.4021 mL | 2.0104 mL | 4.0207 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04184323 | Withdrawn | Drug: EX-527 (Selisistat) Drug: Placebo |
Endometriosis Uterine Diseases |
Wake Forest University Health Sciences | January 2022 | Phase 2 |
Pharmacologic blockade of SIRT1 blunts the orexigenic action of ghrelin.Diabetes.2011 Apr;60(4):1177-85. td> |
Mice lacking p53 do not respond to ghrelin injection.Diabetes.2011 Apr;60(4):1177-85. td> |
Pharmacologic blockade of SIRT1 does not modify the ghrelin-induced GH secretion.Diabetes.2011 Apr;60(4):1177-85. td> |